Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Paradigm Biopharmaceuticals ( (AU:PAR) ) just unveiled an update.
Paradigm Biopharmaceuticals Limited has announced the establishment of an opt-out unmarketable parcel sale facility for shareholders holding less than $500 worth of shares. This initiative aims to provide shareholders with an opportunity to sell their small holdings without incurring brokerage costs, thereby reducing administrative expenses for the company. Approximately 37.2% of the company’s shareholders hold unmarketable parcels, and the facility is designed to streamline operations by consolidating these smaller holdings.
The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.73 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.
More about Paradigm Biopharmaceuticals
Paradigm Biopharmaceuticals Limited is a company operating in the biopharmaceutical industry, focusing on developing and commercializing therapies for unmet medical needs. The company is listed on the Australian Securities Exchange (ASX) under the ticker PAR and has a market presence in Australia, the USA, and Ireland.
Average Trading Volume: 827,862
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$111M
See more insights into PAR stock on TipRanks’ Stock Analysis page.